Issue Date: November 17, 2008
Biotech Investor Forms New Company
FirstPoint Biotech, a San Francisco-based venture capital firm, will acquire a majority interest in London's RCP Therapeutics, a biopharmaceutical company that focuses on nanotechnology and regenerative medicine. As part of the $10 million investment, FirstPoint will establish a separate company to support RCP's R&D in "cosmeceutical" technologies. The remaining firm, to be called FirstPoint RCP Therapeutics, will continue its R&D in regenerative medicine.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society